Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sixty-one cases of the Zollinger-Ellison syndrome, encountered over a 2-year period, have been treated with cimetidine, half of them for over 1 year. Two-thirds of the patients responded to 300 mg of the drug every 6 hr by mouth. Others required up to 600 mg every 6 hr. In adequate doses the drug was highly effective: it controlled pain and dyspepsia, restored weight, abolished diarrhea, and allowed healing of ulcers and other inflammatory conditions. Missed or reduced doses led to rapid return of symptoms. Progression of the basic neoplastic process, with associated secretory drive, was unimpeded. Patient acceptance of the drug was 100 percent, and apart from minor transient abnormalities, gynecomastia (5 cases) and liver dysfunction (3 cases), which resolved while treatment continued, no serious adverse effects were seen. Of 61 patients 48 are still on the drug, 3 who were well controlled were treated surgically, 5 died for reasons unrelated to therapy, and 5 had significant problems. The drug provides an alternative to total gastrectomy and can be recommended with confidence for the suitably selected patients. The drug was also beneficial in some cases of the short bowel syndrome, systemic mastocytosis, and endogenous hyperhistaminemia due to leukemia.
 ...
PMID:Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states. 62 Sep 13

Forty-Five consecutive patients with chronic peptic ulcer disease completed a double-blind controlled trial in which they were given cimetidine 0.8 g daily or placebo in order to evaluate the preventative effect of the drug on ulcer recurrence. On entering the trial all patients had endoscopically healed ulcers. Endoscopy was performed again at 6 and 15 months, or if there were severe epigastric pains. The period of medication was 15 months, and the patients still in remission at that time were observed for a further 9 months. During the course of the study 11 out of 23 patients (47.8%) in the placebo group developed re-ulceration, whereas 4 out of 22 (18.2%) patients relapsed while on cimetidine (p less than 0.05). There were significantly fewer weeks of dyspepsia and better general well-being in the cimetidine group as compared to the placebo group. No early ulcer recurrence or increased rebound acid secretion was noted after cessation of the cimetidine treatment. Vitamin B12 absorption was not affected by the 15-month cimetidine treatment. Two men developed gynaecomastia, one died of myocardial infarction and one had transient sinus bradycardia during cimetidine medication. Cimetidine improves the symptomatic state and postpones ulcer recurrence as long as treatment is maintained.
 ...
PMID:Effect of fifteen months of double-blind treatment with cimetidine and placebo on peptic ulcer recurrence. 678 95